Announced on its homepage: “Alphyn News Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline December 12, 2025 Alphyn Expands P…”.
Observed on the company’s website; business claims are not independently verified.
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
August 2020 – July 2022 · 4 captures · latest observed messagingAlphyn Biologics and AB-101
Alphyn Biologics is creating a new class of drugs, Multi-Target Therapeutics™, for more effective therapies to treat skin disease.